Abbott Laboratories (ABT)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Robert B. Ford
|
Executive Chairman & CEO | 4.43M | 26.48M | 1974 |
|
Mr. Philip P. Boudreau
|
CFO & Executive VP of Finance | 2.1M | -- | 1973 |
|
Mr. Daniel Gesua Sive Salvadori
|
Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 1.52M | 2.14M | 1979 |
|
Mr. Christopher J. Scoggins
|
Executive Vice President of Diabetes Care | 2.06M | 8.59M | 1970 |
|
Ms. Lisa D. Earnhardt
|
Executive VP & Group President of Medical Devices | 2.39M | 4.83M | 1970 |
|
Ms. Sabina Ewing
|
Senior VP of Business & Technology Services and Chief Information Officer | -- | -- | 1974 |
|
Mr. Michael Comilla
|
Vice President of Investor Relations. | -- | -- | -- |
|
Erica L. Battaglia
|
VP and Chief Ethics & Compliance Officer | -- | -- | -- |
|
Ms. Elizabeth C. Cushman
|
Executive VP, General Counsel & Secretary | -- | -- | 1970 |
|
Ms. Melissa Brotz
|
Senior Vice President of Global Marketing & External Affairs | -- | -- | -- |
Abbott Laboratories
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 122,000
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Corporate Governance
Upcoming Events
October 21, 2026 at 12:30 PM UTC
Abbott Laboratories Earnings Date
November 16, 2026 at 12:00 AM UTC
Dividend Date
Recent Events
October 15, 2026 at 12:00 AM UTC
Ex-Dividend Date
May 27, 2026 at 12:00 AM UTC
SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
